Key Highlights

  • Shares fell 11.92% to USD 1.70 in pre-market dealings on November 3, 2026.
  • No company announcement dated November 2 or November 3, 2026 was located.
  • A 50-to-1 share consolidation took effect on October 12, 2026.
  • Nasdaq confirmed minimum bid price compliance in writing on October 23, 2026.
  • A special meeting on December 2, 2026 will vote on a possible split of up to 50 for 1.

What drove Medicus Pharma's pre-market move (down USD 0.2301, 11.92%)

Medicus Pharma (NASDAQ:MDCX) fell 11.92% to USD 1.70 before the open on November 3, 2026. The implied prior close from Monday, November 2, 2026 is about USD 1.93 (calculated).

No company press release or regulatory filing dated November 2 or November 3, 2026 was located. The drop appears to be continued Volatility following a 50-to-1 share consolidation, with only about 1.9 million shares outstanding.

Reverse split and a possible reversal

Medicus completed a 50-to-1 consolidation of its common shares on October 12, 2026, after shareholders approved it on June 3, 2026.

A company proxy statement now asks shareholders to approve a board-discretionary split of up to 50 post-split shares for each pre-split share, which the filing says could largely reverse the consolidation. The board says it does not plan a ratio it expects would push the price below USD 1.00. The meeting is set for December 2, 2026, with a Record Date of October 28, 2026.

Business background and recent updates

Medicus Pharma is an Ontario-incorporated clinical-stage biotech. Its SkinJect program is a dissolvable microneedle patch that delivers doxorubicin to basal cell carcinoma lesions, and it also owns Teverelix, a long-acting GnRH antagonist for advanced prostate cancer and acute urinary retention.

On September 10, 2026, the company said its final Phase 2 clinical study report identified a 200 microgram patch as the lead dose. On September 2, 2026 it signed an agreement with Pfizer (NYSE:PFE) covering CD228V, an early clinical-stage antibody-drug conjugate. Under the 8-K, Medicus paid a USD 12.0 million upfront payment and owes a further USD 15.0 million on the first anniversary, with Pfizer eligible for milestones exceeding USD 1.0 billion.

Balance sheet and listing risks

Nasdaq confirmed compliance with the USD 1.00 minimum bid price on October 23, 2026, after a qualifying period from October 12 to October 23, 2026. The company cautioned that continued compliance is not guaranteed.

Operating cash outflow for 2025 was about USD 22.8 million according to market data, and two secured promissory notes from a USD 22 million Facility mature on November 28, 2027. With the share price this low and a small share count, the stock carries volatility, Liquidity and dilution risk.

What to watch next

The December 2, 2026 special meeting is the next scheduled event, and proxy materials are expected to be mailed around November 10, 2026.

Updates on SkinJect enrollment, the CD228V program and the company's cash position would also matter. Absent new disclosure, price swings may reflect trading dynamics after the consolidation.